•Spyre announced that SPY002 met its primary endpoint in the SKYLINE trial with a statistically significant reduction in disease activity for ulcerative colitis patients.
•Powerfleet reported revenue of $114.5 million for the fourth quarter, an 11% increase year-over-year.
•Q4 income from operations improved to $11.0 million from a prior-year loss, with Adjusted EBITDA up 42% to $26.4 million.
•The company signed a five-year agreement with the South African National Treasury expected to deliver $100 million to $120 million in total contract value.
•Rolls-Royce shares opened higher after its small modular reactor (SMR) unit secured a multi-billion-pound contract to build nuclear reactors in Sweden.
